Seely Dugald M R, Wu Ping, Mills Edward J
Canadian College of Naturopathic Medicine, Toronto, Canada.
BMC Cardiovasc Disord. 2005 Nov 1;5:32. doi: 10.1186/1471-2261-5-32.
Numerous practitioners of both conventional and complementary and alternative medicine throughout North America and Europe claim that chelation therapy with EDTA is an effective means to both control and treat cardiovascular disease. These claims are controversial, and several randomized controlled trials have been completed dealing with this topic. To address this issue we conducted a systematic review to evaluate the best available evidence for the use of EDTA chelation therapy in the treatment of cardiovascular disease.
We conducted a systematic review of 7 databases from inception to May 2005. Hand searches were conducted in review articles and in any of the trials found. Experts in the field were contacted and registries of clinical trials were searched for unpublished data. To be included in the final systematic review, the studies had to be randomized controlled clinical trials.
A total of seven articles were found assessing EDTA chelation for the treatment of cardiovascular disease. Two of these articles were subgroup analyses of one RCT that looked at different clinical outcomes. Of the remaining five studies, two smaller studies found a beneficial effect whereas the other three exhibited no benefit for cardiovascular disease from the use of EDTA chelation therapy. Adverse effects were rare but those of note included a few cases of hypocalcemia and a single case of increased creatinine in a patient on the EDTA intervention.
The best available evidence does not support the therapeutic use of EDTA chelation therapy in the treatment of cardiovascular disease. Although not considered to be a highly invasive or harmful therapy, it is possible that the use of EDTA chelation therapy in lieu of proven therapy may result in causing indirect harm to the patient.
北美和欧洲众多传统医学以及补充与替代医学从业者宣称,使用乙二胺四乙酸(EDTA)进行螯合疗法是控制和治疗心血管疾病的有效手段。这些说法存在争议,并且已经完成了几项关于该主题的随机对照试验。为解决这一问题,我们进行了一项系统评价,以评估使用EDTA螯合疗法治疗心血管疾病的最佳现有证据。
我们对7个数据库从建库至2005年5月进行了系统评价。对手检文章以及所发现的任何试验进行了手工检索。联系了该领域的专家,并检索了临床试验注册库以获取未发表的数据。要纳入最终的系统评价,研究必须是随机对照临床试验。
共找到7篇评估EDTA螯合疗法治疗心血管疾病的文章。其中2篇文章是一项随机对照试验的亚组分析,该试验观察了不同的临床结局。在其余5项研究中,2项较小的研究发现了有益效果,而其他3项研究表明使用EDTA螯合疗法对心血管疾病无益处。不良反应很少见,但值得注意的是,在接受EDTA干预的患者中有几例低钙血症病例和1例肌酐升高病例。
现有最佳证据不支持将EDTA螯合疗法用于治疗心血管疾病。尽管EDTA螯合疗法不被认为是一种高侵入性或有害的疗法,但使用EDTA螯合疗法替代已证实的疗法可能会对患者造成间接伤害。